<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Glenmark Pharmaceuticals has submitted a clarification to BSE and NSE confirming that it is not classified as a 'Large Corporate' under SEBI's circular dated November 26, 2018. As a result, the company is not required to submit the annual large corporate disclosure. The letter is signed by the Company Secretary and the Global CFO, dated April 30, 2026. This is a routine regulatory clarification rather than a new obligation or event.
No material impact on shareholders or the stock price — this is a standard compliance filing confirming Glenmark falls outside the Large Corporate criteria and therefore has no additional disclosure burden under this SEBI framework.